Notifications
Back
Who We are
Who We are
SML Genetree

SML Genetree is a pioneering force in molecular diagnostics and genomic research, dedicated to revolutionizing global healthcare through the practice of 'Smart Medical Life’. As a forward-thinking bio-venture company, we have established ourselves as a leader in developing innovative diagnostic solutions that address critical medical needs worldwide.

SML Genetree stands at the forefront of molecular diagnostics and genomic research, driving innovation and shaping the future of healthcare. As a pioneering bio-venture company, we have established ourselves as a global leader in developing cutting-edge diagnostic solutions that address critical medical needs worldwide.


 +

Through continuous investment in research and development, SML Genetree has developed more than 53 products since its founding and continues to invest in innovation.


 +

SML Genetree has already earned recognition for its quality by supplying products to over 33 countries worldwide and continues to grow and expand its presence in the global market.


 mil+

SML Genetree boasts state-of-the-art production facilities capable of manufacturing over 10 million tests annually, adhering to strict quality control standards under GMP certification.

History

Our journey began in South Korea, where we quickly gained recognition for our groundbreaking work in molecular diagnostics. Today, we have expanded our horizons, positioning ourselves as a research-centric global enterprise committed to advancing human health through scientific excellence and technological innovation.

2022 ~ Present

Leap Forward Period

2024
⦁
New brand “NamuPlex” launch
⦁
CE-IVDR QMS
2023
⦁
GI Bacteria 1,2,3 BKV, CMV Kit approval
⦁
Hi-Seoul company, a promising SME by Seoul City
⦁
Global IP Star company
⦁
Excellent corporate research institute
⦁
Certified as an outstanding company for employee invention compensation
2022
⦁

SARS-CoV-2 Variant Kit approval

⦁

Selected as a 'Main-Biz' technology innovation SME

⦁

Performance sharing company certification

⦁

Designated as a promising company for overseas procurement market entry

⦁

'Materials, Parts, and Equipment' specialist company certification

2020 ~ 2021

Growth Period

2021
⦁
SARS-CoV-2 kit FDA-EUA approval in the U.S. and official approval from MFDS in Korea
⦁
COVID19+RV FAST MFDS approval (35 min, COVID-19, Influenza A/B, RSV)
2020
⦁
Company name changed to “SML Genetree”
⦁

Establishment of U.S. subsidiary “SML Genetree Science”

⦁

SARS-CoV2-FAST Kit obtained first emergency use approval from Korean government

⦁

Selected as BIG3 Innovative Growth Company by Ministry of SMEs and Startups

⦁
Medical Device Quality Management System (ISO13485) certification
2015 ~ 2019

Founding Period

2019
⦁

HPV NGS New Health Technology certification (NECA)

⦁

HLA NGS Kit MFDS approval

⦁
HP-CLA Real-time PCR Kit MFDS approval
2018
⦁

STD 12 types Real-time Kit MFDS approval

⦁
HPV 45 types, 100 types NGS Kit approval
2017
⦁

HLA-B*27 HLA-B*51 Real-time Kit MFDS approval

⦁
MTBC/NTM Real-time Kit MFDS approval
2016
⦁

Quality Management System (ISO 9001) certification

⦁
Genetic testing institution certification
2015
⦁

Establishment of “Genetree Research”

⦁

Completion of in vitro diagnostic medical device manufacturing facility

⦁

K-GMP certification

mobile background

NamuPlex™ is a registered trademark of SML Genetree Co.,Ltd. in South Korea.

Copyright ⓒ 2025 SML Genetree All rights reserved.

mobile background

NamuPlex™ is a registered trademark of SML Genetree Co.,Ltd. in South Korea.

Copyright ⓒ 2025 SML Genetree All rights reserved.